261 related articles for article (PubMed ID: 29933035)
1. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Beebe JD; Liu JY; Zhang JT
Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035
[TBL] [Abstract][Full Text] [Related]
2. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
Huang Q; Zhong Y; Dong H; Zheng Q; Shi S; Zhu K; Qu X; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2020 Feb; 187():111922. PubMed ID: 31810784
[TBL] [Abstract][Full Text] [Related]
3. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
Dong J; Cheng XD; Zhang WD; Qin JJ
J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
[TBL] [Abstract][Full Text] [Related]
4. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
Haftchenary S; Avadisian M; Gunning PT
Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
[TBL] [Abstract][Full Text] [Related]
6. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
[TBL] [Abstract][Full Text] [Related]
7. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.
Masciocchi D; Gelain A; Villa S; Meneghetti F; Barlocco D
Future Med Chem; 2011 Apr; 3(5):567-97. PubMed ID: 21526897
[TBL] [Abstract][Full Text] [Related]
8. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
9. Highlighted STAT3 as a potential drug target for cancer therapy.
Lee H; Jeong AJ; Ye SK
BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
[TBL] [Abstract][Full Text] [Related]
10. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
11. The role of STAT3 signaling in mediating tumor resistance to cancer therapy.
Tan FH; Putoczki TL; Stylli SS; Luwor RB
Curr Drug Targets; 2014; 15(14):1341-53. PubMed ID: 25410411
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 inhibitors: a patent review.
Page BD; Ball DP; Gunning PT
Expert Opin Ther Pat; 2011 Jan; 21(1):65-83. PubMed ID: 21114420
[TBL] [Abstract][Full Text] [Related]
13. Targeting STAT3 in cancer and autoimmune diseases.
Gharibi T; Babaloo Z; Hosseini A; Abdollahpour-Alitappeh M; Hashemi V; Marofi F; Nejati K; Baradaran B
Eur J Pharmacol; 2020 Jul; 878():173107. PubMed ID: 32278856
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
15. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.
Santoni M; Massari F; Del Re M; Ciccarese C; Piva F; Principato G; Montironi R; Santini D; Danesi R; Tortora G; Cascinu S
Expert Opin Investig Drugs; 2015 Jun; 24(6):809-24. PubMed ID: 25746129
[TBL] [Abstract][Full Text] [Related]
16. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.
Bosch-Barrera J; Menendez JA
Cancer Treat Rev; 2015 Jun; 41(6):540-6. PubMed ID: 25944486
[TBL] [Abstract][Full Text] [Related]
17. Discovery, synthesis, and evaluation of small-molecule signal transducer and activator of transcription 3 inhibitors.
Shi ZB; Zhao D; Huang YY; Du Y; Cao XR; Gong ZN; Zhao R; Li JX
Chem Pharm Bull (Tokyo); 2012; 60(12):1574-80. PubMed ID: 23207637
[TBL] [Abstract][Full Text] [Related]
18. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.
Xiang M; Kim H; Ho VT; Walker SR; Bar-Natan M; Anahtar M; Liu S; Toniolo PA; Kroll Y; Jones N; Giaccone ZT; Heppler LN; Ye DQ; Marineau JJ; Shaw D; Bradner JE; Blonquist T; Neuberg D; Hetz C; Stone RM; Soiffer RJ; Frank DA
Blood; 2016 Oct; 128(14):1845-1853. PubMed ID: 27531676
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
20. The salicylanilide derivatives inhibit signal transducer and activator of transcription 3 pathways in A549 lung cancer cells.
Hu M; Ye W; Li J; Zhou P; Chu Z; Huang W
Anticancer Drugs; 2016 Jan; 27(1):41-7. PubMed ID: 26469835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
